Why Is FUSE Stock Rising Today? Fuse Energy Technologies Surges 114% After National Lab Partnership

Fuse Energy Technologies (FUSE) shares surged 114.29% in intraday trading on Monday after the company announced a five-year Cooperative Research and Development Agreement (CRADA) with the Nevada National Security Sites (NNSS). The partnership involves collaboration with Los Alamos National Laboratory and Sandia National Laboratories to validate next-generation fusion technologies.

What Did Fuse Energy Technologies Announce?

Fuse Energy Technologies disclosed the CRADA with NNSS on August 2, 2026, setting the stage for the stock's move during the following regular session. The agreement centers on validating the company's fusion technology platform, with specific work streams targeting tritium handling capabilities and pulsed fusion generators. Los Alamos and Sandia — two of the U.S. Department of Energy's flagship research institutions — will participate in the collaboration alongside NNSS, which has an expanding role in tritium science and nuclear-security research.

Fuse Energy Technologies is a pre-revenue fusion energy startup. Like others in the emerging fusion sector, the company is working toward commercially viable fusion power, a milestone that remains years away for the industry as a whole.

Why Does The NNSS Partnership Matter?

For a small, pre-revenue fusion company, a research agreement with three major U.S. national laboratories represents a notable source of technical validation. CRADAs allow private companies to tap into government expertise, specialized facilities, and research infrastructure — in this case, some of the most advanced fusion and nuclear-science capabilities in the country. Los Alamos and Sandia are both central to the U.S. fusion research ecosystem, and their willingness to collaborate with Fuse may signal to investors that the company's technology approach has enough scientific merit to attract interest from leading government research institutions.

That said, the agreement is an R&D collaboration, not a commercial contract. No financial terms, cost-sharing arrangements, or funding commitments have been publicly disclosed. The value of the partnership at this stage lies in the technical credibility it confers rather than any near-term revenue impact.

What Should Investors Watch Next?

The stock traded around $1.31 during the session, meaning the 114% intraday surge reflects a dollar gain of less than $1. Low-price stocks routinely produce outsize percentage swings, and volume running at roughly 583 times the 20-day average suggests speculative participation alongside the fundamental catalyst. Whether the gains hold through the regular-session close and into subsequent trading days will be an early test of conviction behind the move.

Beyond near-term price action, investors will likely watch for any follow-up disclosures from Fuse about the CRADA's scope, milestone timeline, or funding framework. Additional details could sharpen the market's assessment of how meaningful the national-lab relationship is for the company's technology roadmap. Broader developments in the fusion sector — including progress from better-capitalized competitors and Department of Energy funding cycles — may also influence sentiment around the name.

Fuse remains a pre-revenue company in an industry where commercialization timelines are measured in years, not quarters. The CRADA provides a validation signal, but the path from R&D collaboration to a working commercial reactor is long and uncertain.